Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$10.37 USD
+0.17 (1.67%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $10.40 +0.03 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Oric Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 111 | 92 | 79 | 74 | 29 |
Income After Depreciation & Amortization | -111 | -92 | -79 | -74 | -29 |
Non-Operating Income | 10 | 3 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -101 | -89 | -79 | -74 | -27 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -101 | -89 | -79 | -74 | -27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -101 | -89 | -79 | -74 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -116 | -92 | -77 | -73 | -28 |
Depreciation & Amortization (Cash Flow) | -5 | 0 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -111 | -92 | -79 | -74 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.45 | 39.66 | 37.95 | 21.94 | NA |
Diluted EPS Before Non-Recurring Items | -1.96 | -2.25 | -2.07 | -3.36 | NA |
Diluted Net EPS (GAAP) | -1.96 | -2.25 | -2.07 | -3.36 | NA |
Fiscal Year end for Oric Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 36.02 | 28.99 | 31.43 | 28.68 | 25.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -36.02 | -28.99 | -31.43 | -28.68 | -25.00 |
Non-Operating Income | 4.05 | 3.98 | 4.83 | 3.20 | 2.05 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -31.96 | -25.01 | -28.33 | -25.48 | -22.94 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -31.96 | -25.01 | -28.33 | -25.48 | -22.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -31.96 | -25.01 | -28.33 | -25.48 | -22.94 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 70.35 | 67.35 | 57.46 | 57.40 | 45.65 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.37 | -0.49 | -0.44 | -0.50 |
Diluted Net EPS (GAAP) | -0.45 | -0.37 | -0.49 | -0.44 | -0.50 |